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Survivors of childhood cancer have a higher mortality than the general population. We describe cause-specific long-term mor-
tality in a population-based cohort of childhood cancer survivors. We included all children diagnosed with cancer in Switzer-
land (1976–2007) at age 0–14 years, who survived 5 years after diagnosis and followed survivors until December 31, 2012.
We obtained causes of death (COD) from the Swiss mortality statistics and used data from the Swiss general population to
calculate age-, calendar year-, and sex-standardized mortality ratios (SMR), and absolute excess risks (AER) for different COD,
by Poisson regression. We included 3,965 survivors and 49,704 person years at risk. Of these, 246 (6.2%) died, which was
11 times higher than expected (SMR 11.0). Mortality was particularly high for diseases of the respiratory (SMR 14.8) and cir-
culatory system (SMR 12.7), and for second cancers (SMR 11.6). The pattern of cause-specific mortality differed by primary
cancer diagnosis, and changed with time since diagnosis. In the first 10 years after 5-year survival, 78.9% of excess deaths
were caused by recurrence of the original cancer (AER 46.1). Twenty-five years after diagnosis, only 36.5% (AER 9.1) were
caused by recurrence, 21.3% by second cancers (AER 5.3) and 33.3% by circulatory diseases (AER 8.3). Our study confirms an
elevated mortality in survivors of childhood cancer for at least 30 years after diagnosis with an increased proportion of deaths
caused by late toxicities of the treatment. The results underline the importance of clinical follow-up continuing years after the
end of treatment for childhood cancer.
Cancer is the second most common cause of death in chil-
dren in developed countries.1,2 Improvements in childhood
cancer therapies have drastically increased survival over the
past decades, and 5-year survival rates now exceed 80%.3–6
Unfortunately, about two thirds of childhood cancer survi-
vors experience late effects from the cancer or its treatment;
about a third of these effects are severe or life threatening.7,8
The leading causes of death for children who have survived
5-years after diagnosis are recurrence or progress of the
original cancer, second cancers, and non-neoplastic diseases,
for example, of the circulatory or respiratory system.9–13
Clinical studies are generally designed for assessing efﬁcacy
of treatment protocols typically up to 5 up or 10 years from
diagnosis. Several studies have shown that survivors of child-
hood cancer are not followed systematically into adult-
hood.14,15 Epidemiological studies are therefore necessary to
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monitor long-term mortality on the population level.
Although there are studies on cause-speciﬁc long-term mor-
tality at the population level in the United States, and in
Europe,10,11,16–25 few could include recently diagnosed chil-
dren.9,12 As treatment modalities have changed over the past
decades, studies should include younger cohorts of survivors
who have beneﬁted from newer treatment regimens.26
We used data from the Swiss Childhood Cancer Registry
(SCCR) (i) to compare overall and cause-speciﬁc mortality of
childhood cancer survivors to that of the general population
in Switzerland and describe associated factors, and (ii)
describe cumulative mortality after 5-year survival for differ-
ent causes of death and different diagnostic periods.
Methods
Patient cohort
The study cohort consisted of all 5-year survivors of child-
hood cancer diagnosed before age 15 between January 1,
1976 and December 31, 2007 in Switzerland. Data came from
the population-based Swiss Childhood Cancer Registry
(SCCR).27,28 Recent estimates suggest that it includes 91%
(about 95% since 1995) of all childhood cancer cases diag-
nosed in Switzerland.29 The SCCR has access to medical
records of patients and codes the primary cancer diagnosis in
childhood according to the International Classiﬁcation of
Childhood Cancer (ICCC), 3rd edition.30
Ascertaining cause of death
We obtained coded causes of death by linking records with
mortality statistics in Switzerland.31 The COD statistics
always includes the underlying COD and, if available, one
consecutive, and up to two contributing causes of death, as
coded by the Swiss Federal Statistical Ofﬁce (SFSO). SFSO
coded causes of death according to the International Classiﬁ-
cation of Diseases, 8th revision (ICD-8) for deaths before
1995, and according to the 10th revision (ICD-10) for deaths
after 1995.32,33 For each death, we asked the SFSO for a copy
of the original death certiﬁcate. Death certiﬁcates also contain
notes and remarks about a death, which are not always possi-
ble to be classiﬁed by the ICD of the corresponding period.
Medical personnel of the SCCR had information on date,
site, morphology, treatment and recurrence/progression of
the original cancer diagnosis, and examined death certiﬁcates.
The most probable cause of death from a clinical point of
view was assessed and compared with the ofﬁcially underly-
ing cause of death from mortality statistics. If the clinical
cause of death was different from the ofﬁcial cause of death,
we used the clinical cause of death, and coded it based on
the ICD of the corresponding period. Otherwise we used the
ofﬁcial cause of death and its ICD code. We classiﬁed coded
cause of death into the following subgroups: recurrence or
progression of the primary cancer; second cancers; circulatory
diseases; respiratory diseases; infectious and parasitic diseases;
other medical causes of death; and, external causes of death.
Statistical methods
Examination of long-term mortality for all cohort members
started 5 years after their ﬁrst childhood cancer was diag-
nosed and continued until date of death, loss-to-follow-up, or
December 31, 2012, whichever came ﬁrst. We calculated
standardized mortality ratios (SMR) and absolute excess risks
(AER) overall and for speciﬁc causes of death. SMR and AER
were age- (1-year band), calendar year (1-year band)- and
sex-standardized using Swiss mortality rates as obtained from
the SFSO. SMR was deﬁned as the ratio of observed deaths
divided by the number of expected deaths. AER was deﬁned
as the observed number of deaths minus the expected num-
ber of deaths, divided by the number of person-years at risk,
and expressed by 10,000 person-years. Because there are no
deaths from recurrence the general population, we only
report crude mortality rates for this cause of death. We
stratiﬁed SMR and AER by sex, age at diagnosis (<1 year, 1–
4, 5–9 and 10–14 years), treatment era (1976–1983, 1984–
1991, 1992–1999, 2000–2007) recurrence within 5 years from
diagnosis (no/yes), radiotherapy (no/yes), chemotherapy (no/
yes), HSCT (no/autologous/allogeneic), years from diangosis
((5–14, 15–24,  24), attained age in years (0–19, 20–29, 30–
39, 40–49, 50) and type of childhood cancer. For the all
causes combined we further stratiﬁed ICCC-3 main groups
into subgroups (acute lymphatic leukaemia [ALL], acute
myeloid leukaemia [AML], Hodgkin- and non-Hodgkin lym-
phoma, ependymomas, astrocytomas, primitive neuroectoder-
mal tumors [PNET], medulloblastomas, osteosarcomas,
Ewing sarcomas, rhabdomyosarcomas and other soft-tissue
sarcomas). If data for a variable was missing, we grouped the
missing values in an additional category. We estimated the
simultaneous effect of these factors on risk of death from all
causes of death, from recurrence and from second cancers
using multivariable Poisson regression models that included
all variables. We estimated cumulative mortality (CM) as a
What’s new?
As survivors of childhood cancer age, they are more likely to die prematurely than their peers. The causes of early death, how-
ever, are not fully understood, particularly for recently diagnosed children, who may benefit from newer treatment strategies.
This study shows that for at least three decades after diagnosis, childhood cancer survivors suffer increased mortality. Dis-
ease recurrence initially accounts for the greatest proportion of deaths but is supplanted over time by late treatment-related
toxicities, including second cancers. The findings draw attention to the significance of lifelong follow-up among survivors of
childhood cancer, especially for high-risk individuals.
C
an
ce
r
E
pi
de
m
io
lo
gy
Schindler et al. 323
Int. J. Cancer: 139, 322–333 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
Ta
b
le
1
.
Li
fe
st
a
tu
s,
st
a
n
d
a
rd
iz
e
d
m
o
rt
a
li
ty
ra
ti
o
s
(S
M
R
)
a
n
d
a
b
so
lu
te
e
xc
e
ss
ri
sk
s
(A
E
R
)
fo
r
5
-y
e
a
r
su
rv
iv
o
rs
o
f
ch
il
d
h
o
o
d
ca
n
ce
r
d
ia
g
n
o
se
d
a
t
a
g
e
0
–
1
4
ye
a
rs
b
e
tw
e
e
n
1
9
7
6
a
n
d
2
0
0
7
(S
M
R
a
n
d
A
E
R
a
re
st
a
n
d
a
rd
iz
e
d
a
cc
o
rd
in
g
to
a
g
e
-,
se
x-
,
a
n
d
ca
le
n
d
a
r
ye
a
r)
A
ll
ca
u
se
s
o
f
d
e
a
th
R
e
cu
rr
e
n
t/
p
ro
g
re
ss
iv
e
d
is
e
a
se
1
2
n
d
ca
n
ce
r1
E
li
g
ib
le
C
o
h
o
rt
P
Y
O
b
s/
E
xp
S
M
R
A
ER
2
O
b
s
C
ru
d
e
ra
te
3
O
b
s/
E
xp
S
M
R
A
E
R
2
A
ll
p
a
ti
e
n
ts
3
9
6
5
4
9
7
0
3
.9
2
4
6
/2
2
.3
1
1
.0
(9
.7
-1
2
.5
)
4
5
.0
(3
9
.6
-5
2
)
1
5
3
3
0
.9
(2
6
.4
-3
6
.2
)
3
2
/2
.8
1
1
.6
(8
.2
-1
6
.4
)
5
.9
(4
.0
-8
.5
)
S
e
x M
a
le
2
2
1
5
2
7
8
3
8
.6
1
4
2
/1
6
.7
8
.5
(7
.2
-1
0
.0
)
4
5
.0
(3
7
.9
-5
4
.8
)
8
7
3
1
.3
(2
5
.4
-3
8
.7
)
1
8
/1
.6
1
1
.0
(6
.9
-1
7
.4
)
5
.9
(3
.5
-9
.7
)
Fe
m
a
le
1
7
5
0
2
1
8
6
5
.4
1
0
4
/5
.6
1
8
.4
(1
5
.2
-2
2
.4
)
4
5
.0
(3
6
.8
-5
5
.2
)
6
6
3
0
.3
(2
3
.8
-3
8
.6
)
1
4
/1
.1
1
2
.5
(7
.4
-2
1
)
5
.9
(3
.3
-1
0
.4
)
A
g
e
a
t
d
ia
g
n
o
si
s,
ye
a
rs
<
1
3
7
9
4
5
8
2
.4
1
7
/1
.2
1
4
.3
(8
.9
-2
3
.0
)
3
4
.5
(2
1
.6
-5
8
.3
)
8
1
7
.5
(8
.7
-3
4
.9
)
4
/0
.2
2
4
.1
(9
.0
-6
4
.1
)
8
.4
(3
.1
-2
3
.3
)
1
-4
1
4
0
5
1
7
9
8
8
.8
8
9
/5
.8
1
5
.4
(1
2
.5
-1
8
.9
)
4
6
.3
(3
7
.8
-5
8
.5
)
6
0
3
3
.4
(2
5
.9
-4
3
)
1
4
/0
.7
1
9
.3
(1
1
.4
-3
2
.6
)
7
.4
(4
.3
-1
2
.9
)
5
-9
1
0
7
6
1
3
8
0
2
.3
7
5
/6
.7
1
1
.2
(8
.9
-1
4
.0
)
4
9
.5
(3
9
.2
-6
4
.0
)
5
0
3
6
.4
(2
7
.6
-4
8
.1
)
8
/0
.8
1
0
.4
(5
.2
-2
0
.9
)
5
.3
(2
.3
-1
1
.2
)
1
0
-1
4
1
1
0
3
1
3
3
3
0
.4
6
5
/8
.6
7
.5
(5
.9
-9
.6
)
4
2
.3
(3
1
.3
-5
5
.2
)
3
5
2
6
.5
(1
9
.0
-3
6
.9
)
6
/1
.1
5
.5
(2
.5
-1
2
.1
)
3
.7
(1
.0
-9
.8
)
Tr
e
a
tm
e
n
t
e
ra
1
9
7
6
-
1
9
8
3
5
7
7
1
3
9
7
0
.7
9
8
/9
.4
1
0
.4
(8
.6
-1
2
.7
)
6
3
.4
(5
1
.3
-7
9
.3
)
5
7
4
1
.1
(3
1
.7
-5
3
.3
)
1
5
/1
.2
1
2
.2
(7
.4
-2
0
.3
)
9
.9
(5
.7
-1
7
.2
)
1
9
8
4
-
1
9
9
1
9
0
1
1
7
0
1
7
.5
6
1
/7
.8
7
.8
(6
.1
-1
0
.0
)
3
1
.2
(2
4
.2
-4
2
.4
)
3
1
1
8
.2
(1
2
.8
-2
5
.9
)
9
/0
.9
1
0
.1
(5
.2
-1
9
.4
)
4
.8
(2
.3
-9
.8
)
1
9
9
2
-
1
9
9
9
1
1
8
2
1
3
6
2
4
.2
5
8
/4
.1
1
4
.1
(1
0
.9
-1
8
.2
)
3
9
.5
(3
0
.7
-5
2
.9
)
4
4
3
2
.4
(2
4
.1
-4
3
.5
)
5
/0
.5
1
0
.2
(4
.3
-2
4
.6
)
3
.3
(1
.3
-8
.8
)
2
0
0
0
-
2
0
0
7
1
3
0
5
5
0
9
1
.5
2
9
/1
.0
2
8
.7
(1
9
.9
-4
1
.3
)
5
5
.0
(3
7
.8
-8
0
.2
)
2
1
4
1
.3
(2
6
.9
-6
3
.4
)
3
/0
.2
1
9
.3
(6
.2
-5
9
.9
)
5
.6
(1
.7
-1
8
.4
)
R
e
cu
rr
e
n
ce
N
o
3
4
9
6
4
4
4
7
5
.6
1
3
4
/1
9
.8
6
.8
(5
.7
-8
.0
)
2
5
.4
(2
0
.8
-3
1
.0
)
6
6
1
4
.9
(1
1
.7
-1
9
)
2
4
/2
.5
9
.8
(6
.5
-1
4
.6
)
4
.7
(3
.0
-7
.5
)
Y
e
s
4
6
9
5
2
2
8
.3
1
1
2
/2
.6
4
3
.7
(3
6
.3
-5
2
.6
)
2
1
0
.9
(1
7
4
.7
-2
5
4
.5
)
8
6
1
6
5
.2
(1
3
3
.8
-2
0
4
.1
)
8
/0
.3
2
6
.5
(1
3
.3
-5
3
.0
)
1
4
.9
(7
.3
-3
0
.4
)
R
a
d
io
th
e
ra
p
y
N
o
2
4
1
1
2
8
3
6
7
.2
7
4
/1
0
.9
6
.8
(5
.4
-8
.5
)
2
2
.3
(1
7
.1
-2
9
.1
)
4
8
1
7
.0
(1
2
.8
-2
2
.5
)
4
/1
.4
3
.0
(1
.1
-7
.9
)
0
.9
(0
.2
-4
.1
)
Y
e
s
1
2
5
1
1
7
5
9
0
.6
1
5
9
/9
.5
1
6
.8
(1
4
.4
-1
9
.6
)
8
6
.1
(7
3
.1
-1
0
1
.3
)
9
9
5
6
.4
(4
6
.4
-6
8
.7
)
2
6
/1
.2
2
2
.4
(1
5
.3
-3
2
.9
)
1
4
.2
(9
.4
-2
1
.1
)
U
n
k
n
o
w
n
3
0
3
3
4
7
4
.1
1
3
/1
.9
6
.7
(3
.9
-1
1
.6
)
3
0
.2
(1
6
.2
-5
6
.2
)
6
1
6
.1
(7
.2
-3
5
.9
)
2
/0
.3
8
.0
(2
.0
-3
1
.8
)
5
.1
(1
.2
-2
2
.0
)
C
h
e
m
o
th
e
ra
p
y
N
o
7
3
3
8
5
6
0
.5
1
5
/3
.6
4
.2
(2
.5
-6
.9
)
1
4
.2
(7
.7
-2
6
.3
)
9
1
0
.5
(5
.5
-2
0
.3
)
0
/0
.5
N
A
N
A
Y
e
s
2
9
8
1
3
7
6
4
4
.3
2
1
8
/1
6
.9
1
2
.9
(1
1
.3
-1
4
.8
)
5
3
.7
(4
6
.6
-6
2
.0
)
1
3
8
3
6
.8
(3
1
.1
-4
3
.5
)
3
0
/2
.1
1
4
.5
(1
0
.2
-2
0
.8
)
7
.4
(5
.0
-1
0
.8
)
U
n
k
n
o
w
n
2
5
1
3
4
9
9
.1
1
3
/1
.9
6
.9
(4
.0
-1
2
.0
)
3
2
.6
(1
7
.6
-6
0
.4
)
6
1
7
.3
(7
.8
-3
8
.4
)
2
/0
.2
8
.2
(2
.1
-3
2
.9
)
5
.5
(1
.3
-2
3
.6
)
Tr
a
n
sp
la
n
ta
ti
o
n
N
o
3
4
6
7
4
4
1
1
9
.1
1
9
4
/1
9
.6
9
.9
(8
.6
-1
1
.4
)
3
9
.8
(3
4
.1
-4
6
.5
)
1
2
3
2
8
.0
(2
3
.4
-3
3
.4
)
2
0
/2
.4
8
.3
(5
.3
-1
2
.8
)
3
.9
(2
.3
-6
.4
)
A
ll
o
g
e
n
e
ic
9
4
9
3
8
.0
2
0
/0
.4
4
8
.5
(3
1
.3
-7
5
.2
)
2
0
8
.9
(1
3
3
.5
-3
2
6
.7
)
9
9
8
.2
(5
1
.1
-1
8
8
.7
)
7
/0
1
4
7
.8
(7
0
.5
-3
1
0
.1
)
7
5
.8
(3
6
.0
-1
5
9
.9
)
A
u
to
lo
g
o
u
s
7
4
6
1
7
.7
1
6
/0
.2
6
5
.6
(4
0
.2
-1
0
7
.1
)
2
5
6
.4
(1
5
6
.3
-4
2
0
.6
)
1
3
2
1
0
.5
(1
2
2
.2
-3
6
2
.4
)
2
/0
7
2
.8
(1
8
.2
-2
9
1
.1
)
3
1
.9
(7
.8
-1
3
0
.3
)
U
n
k
n
o
w
n
3
3
0
4
0
2
9
.2
1
6
/2
.1
7
.6
(4
.7
-1
2
.4
)
3
4
.4
(1
9
.6
-6
0
.4
)
7
1
7
.5
(8
.3
-3
6
.7
)
3
/0
.3
1
0
.9
(3
.5
-3
4
.0
)
7
.1
(2
.2
-2
3
.5
)
C
an
ce
r
E
pi
de
m
io
lo
gy
324 Long-term mortality in survivors of childhood cancer
Int. J. Cancer: 139, 322–333 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
Ta
b
le
1
.
Li
fe
st
a
tu
s,
st
a
n
d
a
rd
iz
e
d
m
o
rt
a
li
ty
ra
ti
o
s
(S
M
R
)
a
n
d
a
b
so
lu
te
e
xc
e
ss
ri
sk
s
(A
E
R
)
fo
r
5
-y
e
a
r
su
rv
iv
o
rs
o
f
ch
il
d
h
o
o
d
ca
n
ce
r
d
ia
g
n
o
se
d
a
t
a
g
e
0
–
1
4
ye
a
rs
b
e
tw
e
e
n
1
9
7
6
a
n
d
2
0
0
7
(S
M
R
a
n
d
A
E
R
a
re
st
a
n
d
a
rd
iz
e
d
a
cc
o
rd
in
g
to
a
g
e
-,
se
x-
,
a
n
d
ca
le
n
d
a
r
ye
a
r)
(C
o
n
ti
n
u
e
d
)
A
ll
ca
u
se
s
o
f
d
e
a
th
R
e
cu
rr
e
n
t/
p
ro
g
re
ss
iv
e
d
is
e
a
se
1
2
n
d
ca
n
ce
r1
E
li
g
ib
le
C
o
h
o
rt
P
Y
O
b
s/
E
xp
S
M
R
A
ER
2
O
b
s
C
ru
d
e
ra
te
3
O
b
s/
E
xp
S
M
R
A
E
R
2
Y
e
a
rs
fr
o
m
ca
n
ce
r
d
ia
g
n
o
si
s,
ye
a
rs
5
-1
4
3
9
6
5
3
0
2
4
7
.2
1
9
9
/1
0
.9
1
8
.3
(1
5
.9
-2
1
.0
)
6
2
.2
(5
3
.9
-7
2
.2
)
1
3
9
4
6
.1
(3
9
.1
-5
4
.5
)
2
1
/1
.2
1
8
.2
(1
1
.8
-2
7
.9
)
6
.6
(4
.2
-1
0
.4
)
1
5
-2
4
2
2
0
3
1
5
0
3
4
.2
3
0
/8
.4
3
.6
(2
.5
-5
.1
)
1
4
.4
(8
.4
-2
3
.1
)
1
0
6
.7
(3
.6
-1
2
.4
)
8
/0
.9
8
.6
(4
.3
-1
7
.1
)
4
.7
(2
.0
-1
0
.2
)

2
5
8
8
2
4
4
2
2
.5
1
7
/3
.1
5
.6
(3
.5
-8
.9
)
3
1
.5
(1
5
-5
3
.8
)
4
9
.1
(1
.1
-2
7
5
0
.6
)
3
/0
.7
4
.5
(1
.4
-1
3
.9
)
5
.3
(0
.8
-2
4
.7
)
A
tt
a
in
e
d
a
g
e
,
ye
a
rs
0
-1
9
1
4
6
2
7
2
3
2
.7
1
7
4
/1
.1
1
6
1
.8
(1
3
9
.5
-1
8
7
.8
)
2
3
9
.1
(2
0
4
.5
-2
7
6
.2
)
1
2
4
1
7
2
.1
(1
4
4
.3
-2
0
5
.2
)
2
1
/0
.2
9
7
.2
(6
3
.4
-1
4
9
.0
)
2
8
.8
(1
8
.7
-4
4
.4
)
2
0
-2
9
1
3
9
0
1
7
1
8
4
.5
4
8
/5
.6
8
.6
(6
.5
-1
1
.4
)
2
4
.7
(1
4
.0
-3
0
.9
)
2
4
1
4
.0
(9
.4
-2
0
.9
)
5
/0
.6
8
.2
(3
.4
-1
9
.7
)
2
.6
(0
.7
-7
.0
)
3
0
-3
9
8
5
6
1
8
3
0
3
.8
1
3
/9
.6
1
.4
(0
.8
-2
.3
)
1
.9
(0
.0
-3
4
.1
)
2
1
.1
(0
.3
-4
.4
)
4
/1
.1
3
.7
(1
.4
-9
.9
)
1
.6
(0
.1
-9
.3
)
4
0
-4
9
2
5
4
6
8
8
9
.6
1
1
/6
.0
1
.8
(1
.0
-3
.3
)
7
.3
(0
.7
-3
2
.9
)
3
4
.4
(1
.4
-1
3
.6
)
2
/0
.8
2
.4
(0
.6
-9
.5
)
1
.7
(0
.0
-1
1
0
.2
)
5
0
3
9
3
.4
0
/0
.1
N
A
N
A
0
N
A
0
/0
.0
N
A
N
A
C
h
il
d
h
o
o
d
ca
n
ce
r
d
ia
g
n
o
si
s4
I.
Le
u
k
a
e
m
ia
1
2
8
9
1
6
4
6
4
.3
1
0
6
/7
.0
1
5
.1
(1
2
.5
-1
8
.2
)
6
0
.1
(4
9
.2
-7
3
.8
)
6
8
4
1
.5
(3
2
.7
-5
2
.7
)
1
6
/0
.9
1
8
.6
(1
1
.4
-3
0
.4
)
9
.2
(5
.4
-1
5
.4
)
Ia
.
A
LL
5
7
6
1
4
9
0
8
.2
8
6
/6
.4
1
3
.4
(1
0
.9
-1
6
.6
)
5
3
.7
(4
2
.8
-6
7
.4
)
Ib
.
A
M
L
6
7
9
1
2
2
2
.1
1
4
/0
.5
2
8
.2
(1
6
.7
-4
7
.5
)
1
0
9
.7
(6
3
.5
-1
8
9
.5
)
II
.
Ly
m
p
h
o
m
a
5
7
6
7
8
9
3
.8
2
5
/5
.0
5
.0
(3
.4
-7
.4
)
2
5
.3
(1
4
.3
-4
0
.0
)
8
1
0
.2
(5
.1
-2
0
.4
)
5
/0
.6
8
.3
(3
.5
-2
0
.0
)
5
.6
(1
.7
-1
5
.1
)
II
a
.
H
o
d
g
k
in
ly
m
p
h
o
m
a
2
3
7
3
2
5
1
.6
1
6
/2
.2
7
.3
(4
.5
-1
1
.9
)
3
9
.8
(2
1
.8
-7
2
.8
)
II
b
.
N
o
n
-H
o
d
g
k
in
ly
m
p
h
o
m
a
1
9
1
2
6
4
0
.6
8
/1
.7
4
.7
(2
.3
-9
.3
)
2
5
.0
(1
0
.9
-5
7
.7
)
II
I.
C
N
S
tu
m
o
u
rs
6
7
9
6
9
2
.5
5
1
/3
.3
1
5
.7
(1
1
.9
-2
0
.6
)
6
3
.9
(4
8
.6
-8
6
.5
)
4
1
5
4
.9
(4
0
.4
-7
4
.6
)
3
/0
.4
7
.4
(2
.4
-2
3
.0
)
3
.5
(1
.1
-1
2
.6
)
II
Ia
.
E
p
e
n
d
ym
o
m
a
6
2
6
9
2
.5
1
1
/0
.3
3
6
.8
(2
0
.4
-6
6
.5
)
1
5
5
.7
(8
5
.3
-2
8
4
.5
)
II
Ib
.
A
st
ro
cy
to
m
a
2
9
4
3
1
0
4
.6
1
5
/1
.2
1
2
.5
(7
.5
-2
0
.7
)
4
5
.9
(2
7
.0
-7
8
.2
)
II
Ic
.
P
N
E
T
2
2
2
0
5
.0
1
/0
.1
1
5
.3
(2
.2
-1
0
8
.4
)
4
4
.5
(5
.2
-3
8
1
.9
)
II
Ic
.
M
e
d
u
ll
o
b
la
st
o
m
a
1
0
9
1
3
1
9
.1
1
7
/0
.7
2
5
.9
(1
6
.1
-4
1
.7
)
1
2
3
.5
(7
5
.2
-2
0
2
.7
)
IV
.
N
e
u
ro
b
la
st
o
m
a
2
1
8
2
7
4
9
.4
1
5
/0
.8
1
8
.9
(1
1
.4
-3
1
.3
)
5
1
.7
(3
1
.2
-8
8
.9
)
1
0
3
6
.4
(1
9
.6
-6
7
.6
)
1
/0
.1
9
.5
(1
.3
-6
7
.2
)
3
.3
(0
.4
-2
8
.5
)
V
.
R
e
ti
n
o
b
la
st
o
m
a
1
3
1
1
7
3
3
.1
4
/0
.5
8
.3
(3
.1
-2
2
.1
)
2
0
.3
(6
.3
-6
1
.7
)
0
N
A
3
/0
.1
4
7
.2
(1
5
.2
-1
4
6
.5
)
1
6
.9
(5
.3
-5
3
.9
)
V
I.
R
e
n
a
l
tu
m
o
u
rs
2
3
5
3
0
5
6
.4
6
/0
.9
6
.8
(3
.1
-1
5
.2
)
1
6
.8
(7
.5
-4
3
.1
)
3
9
.8
(3
.2
-3
0
.5
)
2
/0
.1
1
6
.6
(4
.2
-6
6
.4
)
6
.2
(1
.5
-2
6
.7
)
V
II
.
H
e
p
a
ti
c
tu
m
o
u
r
2
8
3
2
8
.2
1
/0
.1
9
.0
(1
.3
-6
3
.6
)
2
7
.1
(3
.9
-2
2
4
.2
)
1
3
0
.5
(4
.3
-2
1
6
.3
)
0
/0
.0
N
A
N
A
V
II
I.
B
o
n
e
tu
m
o
u
rs
1
5
9
1
8
6
3
.2
1
5
/1
.1
1
4
.2
(8
.6
-2
3
.6
)
7
4
.8
(4
3
.4
-1
2
8
.9
)
1
0
5
4
.8
(2
9
.5
-1
0
1
.9
)
1
/0
.1
7
.8
(1
.1
-5
5
.3
)
4
.8
(0
.5
-4
6
.9
)
V
II
Ia
.
O
st
e
o
sa
rc
o
m
a
7
4
8
8
8
.8
5
/0
.5
9
.1
(3
.8
-2
2
.0
)
5
1
.0
(1
9
.5
-1
3
3
.9
)
V
II
Ic
.
E
w
in
g
sa
rc
o
m
a
7
7
7
9
6
.5
1
0
/0
.4
2
5
.8
(1
3
.9
-4
7
.9
)
1
1
9
.5
(6
2
.4
-2
2
9
.1
)
C
an
ce
r
E
pi
de
m
io
lo
gy
Schindler et al. 325
Int. J. Cancer: 139, 322–333 (2016) VC 2016 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of
UICC
function of time since diagnosis for different causes of death
and different diagnostic periods. We used logrank test for
trend to test for trends in CM and treated causes of death,
other than the one under observation, as competing risks
using the “stcompet” command in STATA. Between 1976
and 1981, the SCCR mainly registered children who were
included in clinical studies. We assume that certain tumors,
especially those not treated in a specialized pediatric cancer
center, were not registered in the SCCR. In a sensitivity anal-
ysis, we repeated our main analysis of overall SMR consider-
ing only cases diagnosed 1985–2007. p-values were two sided;
we considered a p values of 0.05 to be statistically signiﬁ-
cant. STATA, version 13 was used for all statistical analyses
(StataCorp. 2013. Stata Statistical Software: Release 13.1.Col-
lege Station, TX: StataCorp LP).
Results
Cohort characteristics
Of 5,190 children diagnosed with cancer in Switzerland
between 1976 and 2007, 3,965 (76%) were long-term survi-
vors for 5 years or more. By the study exit date, 246 (6.2%)
of them had died, 113 (2.9%) were lost-to-follow-up, and
3,606 (91.0%) were still alive. COD was available for 226
(92.0%) of the deceased. In 23 of 226 cases (10.2%), hand-
written information on the death certiﬁcate or the patients’
medical history caused us to recode the ofﬁcial COD from
primary cancer to a second cancer (N5 13), or a non-cancer
late fatality (n5 10). We included 49’704 person-years at risk
from 5-year survival. Mean follow-up time was 17.5 (95%
conﬁdence interval [CI] 17.3–17.8) years from diagnosis;
median was 16.5 years (range 5.0 to 36.9). Information on
radiotherapy was missing for 303 patients (7.6%), on chemo-
therapy for 251 patients (7.6%), and on HSCT for 330
patients (8.3%).
Overall mortality
Survivors were 11 times more likely to die than their peers in
the general population (SMR 11.0). There were 45 extra
deaths (AER 45.0) per 10,000 person-years (Table 1). SMR
was higher in females (SMR 18.4) than males (SMR 8.5),
while the AER was comparable. The SMR was higher in chil-
dren diagnosed at ages <1 year (SMR 14.3) and 1–4 years
(SMR 15.4) than in those diagnosed at ages 5–9 (SMR 11.2)
and 10–14 (SMR 7.5). Those who had had recurrent disease
within 5 years of diagnosis were likely to have considerably
higher mortality from any cause (SMR 43.7) than those with-
out recurrence during that period (SMR 6.8). Children who
had autologous (SMR 65.6) or allogeneic HSCT (SMR 48.5)
in the ﬁrst 5 years after diagnosis had signiﬁcantly higher
SMR compared to those without HSCT (SMR 9.9). The SMR
declined with increasing follow-up time and attained age
(p< 0.001 for trend). However, signiﬁcant excess mortality
remained beyond 24 years from diagnosis (SMR 5.6). Num-
ber of excess deaths was largest during the ﬁrst 10 years afterTa
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5-year survival (AER 62.2), declined thereafter between 15
and 24 years after diagnosis (AER 14.4) and increased again
beyond 24 years after diagnosis (AER 31.5). We observed the
greatest SMRs among survivors of ependymoma (SMR 36.8),
AML (SMR 28.2), medulloblastoma (SMR 25.9) and Ewing
sarcoma (25.8). AER varied widely by primary cancer diagno-
sis and was largest for those diagnosed with ependymoma
(AER 155.7), Ewing sarcoma (AER 119.5) and AML (AER
109.7). In regard of ICCC-3 main group, the SMR was high-
est for children diagnosed with neuroblastoma (SMR 18.9),
CNS tumours (SMR 15.7), leukaemia (SMR 15.1) and bone
tumours (SMR 14.2). AER was largest for bone tumours
(AER 74.8), CNS tumours (AER 63.9), leukaemia (AER 60.1)
and neuroblastoma (AER 51.7).
Cause-specific mortality
SMRs were signiﬁcantly elevated for deaths from second can-
cers (SMR 11.6), diseases of the circulatory system (SMR
12.7), diseases of the respiratory system (SMR 14.8) and
infectious diseases (SMR 7.3) (Table 2). Mortality was not
increased for deaths due to other medical causes (SMR 0.9)
and external causes (SMR 1.0). Highest number of excess
deaths was observed for deaths due to recurrence or progres-
sion of the original cancer (AER 30.9), second cancer (AER
5.9) and circulatory disease (AER 2.9). For diseases of the
respiratory system, and infectious diseases, AERs were <1
per 10’000 person-years.
We then proceeded to determine potential explanatory
factors for all cause mortality, recurrence, second cancers and
circulatory diseases. To do this, we stratiﬁed SMR and AER
by different explanatory factors. Crude mortality rate for
recurrence or progression of the original cancer, which can
be interpreted as an AER, was highest in survivors of CNS
tumours (AER 54.9) and bone tumours (AER 54.8) (Table 1).
Number of excess deaths due to recurrence was highest at 5
to 14 years from diagnosis (AER 46.1) and declined to below
10 excess deaths beyond 14 years from diagnosis. Multivari-
able analysis showed that children who suffered from recur-
rent disease during the ﬁrst 5 years after diagnosis were at
higher risk of death due to recurrence or progression (RR
8.2) than those without recurrence (Table 3). Children
treated with radiotherapy (RR 2.2), chemo therapy (RR 4.4),
or autologous HSCT (RR 3.7) in the ﬁrst 5 years after diag-
nosis were more likely to die from recurrence than those
who did not receive radiotherapy, chemotherapy or HSCT.
SMR for second cancers was highest for children origi-
nally diagnosed with retinoblastoma (SMR 47.2) and leukae-
mia (SMR 18.6) (Table 1). Mortality due to second cancers
was relatively stable over follow-up time with 6.6 excess
deaths at 5–14 years after diagnosis, 4.7 at 15–24 years and
5.3 excess deaths beyond 24 years from diagnosis. Multivari-
able analysis showed that children treated with radiotherapy
(RR 9.2), allogeneic HSCT (RR 12.5) or autologous HSCT
(RR 6.3) had a higher risk for death due to second primary
cancer than those without radiotherapy or HSCT (Table 3).
Those who had had recurrent disease within the ﬁrst 5 years
after diagnosis had the same risk for mortality due to second
cancers as those who did not have recurrence.
From 5–14 years after diagnosis, recurrence accounted for
78.9% of all excess deaths, second cancers for 11.3%, circula-
tory diseases for 4.9% and all other causes of death for 2.9%
(Table 4). Beyond 24 years after diagnosis the proportion
decreased to 36.5% for recurrence, but increased to 21.3% for
second cancers, to 33.3% for circulatory diseases and to 8.9%
for all other causes of death.
Cumulative mortality
Cumulative mortality (CM), which can be interpreted as a
probability of death, was 8.8% (CI 6.4–15.0) at 30 years after
diagnosis for all 5-year survivors (Fig. 1). The CM for death
from recurrence or progression increased steeply with time
from diagnosis, to 3.3% (CI 2.8-4.0) at 10 years. It then
Table 2. Observed and expected numbers of death, standardized mortality ratio (SMR) and absolute excess risk (AER) for specific causes of
death
Obs/Exp SMR (95% CI) AER1 (95% CI)
All causes of death 226/22.2 10.2 (8.9-11.6) 41.2 (36.1-48)
Recurrent/progressive disease 153/0.0 NA 30.9 (26.4-36.2)
All causes except recurrence 73/22.2 3.3 (2.6-4.1) 10.3 (7.2-13.8)
2nd cancer 32/2.8 11.6 (8.2-16.4) 5.9 (4.0-8.5)
All causes except cancer 41/19.5 2.1 (1.6-2.9) 4.3 (2.1-7.2)
Diseases of the circulatory system 16/1.3 12.7 (7.8-20.7) 2.9 (1.5-4.7)
Diseases of the respiratory system 4/0.3 14.8 (5.6-39.4) 0.7 (0.3-2.2)
Infectious diseases 4/0.5 7.3 (2.7-19.4) 0.7 (0.2-2.2)
External causes 13/12.8 1 (0.6-1.8) 0.0 (0.0-7.4)
Other causes2 4/4.6 0.9 (0.3-2.3) NA
1Per 10’000 person-years at risk.
2All other causes of death other than the ones aforementioned.
Abbreviations: Obs: observed; Exp: expected; CI: confidence interval.
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increased at a slower pace, to 5.2% (CI 4.3-6.3) at 30 years
from diagnosis. The CM for all causes except recurrence was
10.8% (CI 0.6-1.2) at 10 years from diagnosis, but increased
continuously to 3.5% (CI 2.6–4.6) at 30 years from diagnosis.
CM decreased signiﬁcantly with time of diagnosis for 5-
year survivors of childhood cancer (Fig. 2). The probability
of dying from all causes of death combined within the next 5
years dropped most markedly between the periods 1976–
1983 (9.0%, CI 6.9–11.6) and 1984–1993 (3.9%, CI 1.7–3.8).
CM at 10 years after diagnosis did not differ signiﬁcantly
between later periods due to low numbers. But we observed
an on-going trend for decreasing CM when looking at the
total follow-up time of all 4 periods (p-trend< 0.001).
Sensitivity analysis
We further performed a sensitivity analysis by considering
only cases diagnosed since 1985. Results did not materially
change: the overall SMR was 11.4 (CI 9.7–13.4) and the AER
38.6 (CI 32.5–45.9).
Discussion
This population-based cohort of 5-year survivors of child-
hood cancer showed that this group of patients remains at
signiﬁcantly increased risk for death 30 years after diagnosis.
At 5–14 years after diagnosis, 79% of all extra deaths were
caused by recurrence of the primary cancer, but this propor-
tion decreased to 37% 24 years from diagnosis. In contrast,
the proportion of extra deaths from second cancers, circula-
tory diseases, respiratory diseases and other diseases
increased steadily with time from diagnosis and accounted
for 64% of all deaths occurring beyond 24 from diagnosis.
Cumulative mortality beyond 5 years after diagnosis
decreased signiﬁcantly over time.
The SMR estimated in our study was consistent with
results from the British Childhood Cancer Survivor study
(BCCSS) (SMR 10.7), and was somewhat higher than had
been reported from the Childhood Cancer Survivor study
(CCSS) (SMR 8.4) and the Nordic countries (SMR 8.3).10,11,20
A study from Scotland, similar in size to our own, analysed
long-term cause-speciﬁc mortality among children, adoles-
cents and young adults with cancer; this study reported an
overall SMR for childhood cancer (age at diagnosis 0–14
years) of 11.0 similar to ours, but found a slightly higher
number of AER (51).12 Similar to our study, the CCSS
reported highest SMRs among survivors of Ewing sarcomas
and medulloblastomas or PNET. However, the CCSS did not
differentiate between PNET and medulloblastomsa.20 In con-
trast the CCSS found a lower SMR for AML (SMR 9.5) com-
pared to our study. In terms of ICCC-3 main groups, the
high overall SMR for leukaemia and CNS tumours
(SMR> 15) estimated in our study were comparable to ﬁnd-
ings from other studies.11,12,20 However, most other studies
reported a lower overall SMR for neuroblastomas. In our
study, SMR for deaths due to diseases of the respiratory sys-
tem, circulatory system and second cancer was largest
(SMR> 10). This was slightly higher than reported in the
Table 4. Absolute excess risks (AER) by years from diagnosis as a
proportion of total AER
AER (%1) by years from diagnosis
Cause of death 5-14 15-24 >24
Recurrent/progressive
disease
46.1 (78.9) 6.7 (51.0) 9.1 (36.5)
Second cancer 6.6 (11.3) 4.7 (36.0) 5.3 (21.3)
Circulatory disease 2.8 (4.9) 1.7 (12.8) 8.3 (33.3)
Other causes of death 2.9 (5) NA 2.2 (8.9)
All deaths2 58.4 13.1 24.9
1Proportion of total AER during specific time period since diagnosis.
2Number of AER differs slightly from number indicated in Table 1 due
to unknown cause of death in 20 patients.
Figure 1. Cause-specific probability of death for different causes of
death in 5-year survivors of childhood cancer diagnosed at age
0–14 years between 1976 and 2007 (cumulative mortality treating
cause of death other than the one under observation as competing
risks).
Figure 2. Cumulative mortality from all causes in 5-year survivors
of childhood cancer diagnosed at age 0–14 years according to the
specific treatment area. p values form log-rank test for trend.
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BCCSS (for all three causes of death) and in the Nordic study
(for circulatory diseases and second cancers).11,24 Similar to
our study SMR was highest for diseases of the respiratory
system (SMR 34.9) as reported in a study from the Nordic
countries.10 In our study, mortality from external causes
(including suicide) was not elevated, in contrast to the
BCCSS.11 It is important to note, that there is some heteroge-
neity regarding age at diagnosis of the primary cancer, calen-
dar period of diagnosis and length of follow-up in comparing
studies. The decrease of AER for deaths due to recurrence
and simultaneous increase of AER to other causes of death
over study time was consistent with ﬁndings from the
BCCSS, although it has a longer period of follow-up.11 Other
studies did not compare cause speciﬁc SMR or AER at differ-
ent times since diagnosis. Crude mortality rates for recur-
rence deaths estimated in our study were highest for CNS
tumours bone tumours and leukaemia. This is comparable to
results form the BCCSS, which reported crude rates for
recurrence deaths to be highest for PNET, leukaemia (exclud-
ing ALL), CNS tumours (excluding PNET) and bone
tumours.11 Most other studies did not report crude rates for
deaths due to recurrence for underling cancer diagnosis. Like
in our study, the BCCSS reported high SMR for second can-
cers for children diagnosed with retinoblastoma. However,
we were not able to distinguish between heritable and non-
heritable retinoblastoma and we assume that the heritable
form of the disease drove the high SMR for retinoblastoma
rather than treatment related causes. Like our study, studies
from United States, United Kingdom and the Nordic coun-
tries showed that CM from recurrence increased during the
ﬁrst 10 years from diagnosis, and then levelled off, while CM
for second cancers and circulatory diseases, increased contin-
uously with follow-up time. In 2012 Garwicz et al. explored
temporal trends in CM using data from the Nordic coun-
tries.10 Similar to our study the most marked decrease in CM
was observed for patients diagnosed during the 1980 sec
compared to those diagnosed during the 1970 sec. However,
the decrease in cumulative mortality from the ﬁrst to the
subsequent diagnostic period be interpreted cautiously. As
commonly is the case in cancer registration, completeness of
the SCCR was somewhat lower in its early years compared to
today. Because the SCCR started as a clinical registry and
registered mostly children enrolled in clinical studies, we
assume that certain cancers were not registered completely,
especially low grade CNS tumours and melanomas. The
cumulative mortality observed for children diagnosed 1976–
1984 may therefore have been overestimated. However, a sen-
sitivity analysis showed that overall estimates of all cause
SMR and AER did not change substantially when excluding
the ﬁrst period from the analysis (1976–1984).
Excess mortality due to second cancers, circulatory dis-
eases and diseases of the respiratory system are likely caused
by late effects of cancer treatment.13,34–38 Second cancers are
widely accepted as a late effect of radiotherapy during the
treatment, but also speciﬁc chemotherapeutic agents might be
involved in the development of second cancers. Some second
cancers might also be attributable to familial cancer syn-
dromes like heritable retinoblastoma and Li–Fraumeni syn-
drome.39–41 Thus, the elevated SMR for second cancers in
children diagnosed with retinoblastoma is a combination of
treatment related late toxicities and genetic predisposition.
Circulatory diseases may also be a late complication of child-
hood cancer therapy, primarily related to chest radiation or
anthracyclines. Similar to the BCCSS and the CCSS cohort,
we have also demonstrated adverse respiratory late effects
among childhood cancer survivors. However, this should be
interpreted cautiously in the context of this rare disease with
only 4 (1.8%) out of 226 late deaths attributable to it.
One of the main advantages of this study was the combi-
nation of three resources. First, information on original child-
hood cancer diagnosis came from the population-based
SCCR. The SCCR is very complete (>95% since 1995) and
its not susceptible to response bias compared to
questionnaire-based studies. Second, clinical data such as
information on treatment and follow-up was reported
directly from the nine specialized paediatric oncology clinics
throughout Switzerland. We had access to most medical
records and could validate treatment and follow-up data.
Third, we had access to ofﬁcial death certiﬁcates and were
able to validate code causes of death from ofﬁcial mortality
statistics. This is important since it has been shown that
deaths attributable to recurrence of the primary cancer can
be overestimated, and consecutive or contributing causes of
death (which might reﬂect therapy induced late effects) can
be underestimated.24,42 Another advantage of our study was
that we were able to include recently diagnosed patients (up
to 2007), which many other studies could not do.11,18,20 But,
our study was smaller than other studies, so we had limited
capacity to perform subgroup analyses. Another limitation of
our study was the lack of detailed data on radiotherapy and
chemotherapy exposures and lack of data on applied dosages.
Therefore, we were no able to analyse the effect of dose-
response patterns on risk of morality. We validated COD of
childhood cancer survivors, since cancer deaths were most
probably overestimated. We must assume that this was also
true for cancer deaths in the ofﬁcial statistics. If true, this
would have led to an overestimation of expected deaths due
to (second) cancer in our analysis and thus to an underesti-
mation of second cancer speciﬁc SMR. The form of the death
certiﬁcate changed over the study period. However, data
items concerning causes of death remained unchanged. Fur-
ther, there has been a change in the coding system in the
mortality statistics in Switzerland from ICD-8 to ICD-10 and
an adaption of coding rules, which could introduce breaks
into time series of disease coding. However, since we classi-
ﬁed COD into broad categories, we assume that this break in
the coding system and rules did not affect the results of our
study. Deaths due to late effects of the treatment may have
declined over time due to better follow-up care. If late effects
become less fatal, mortality may become a less reliable
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indicator of the incidence of these late effects. This suggests
that future studies should also address morbidity, not only
mortality.
Clinicians and patients need information on long-term
outcomes, and especially mortality, to make sound decisions
about treatment and follow-up. We demonstrated the useful-
ness of linking baseline cancer registry data and clinical data
on treatment to routinely collected mortality records to mon-
itor fatal late-effects inexpensively. Our results underline the
importance of follow-up programs lasting years after the end
of treatment for childhood cancer, and we suggest the use of
standardized risk-adapted protocols for monitoring health
conditions in the growing population of childhood cancer
survivors. In absolute numbers, second cancers and circula-
tory disease account for most excess deaths in survivors diag-
nosed over 24 years ago, but this population is also less likely
to attend follow-up than those were more recently
diagnosed.43 Our results underline the importance of follow-
up programs lasting years after the end of treatment for
childhood cancer, and we suggest a standardized protocol
would be useful for detailed monitoring of health conditions
in detail in the growing population of childhood cancer
survivors.
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